Drug Trial Radar · NCT07739966
A Study of DS-3939a in Participants With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Oct 13, 2026
Primary completion
Jul 31, 2030
Study completion Jan 29, 2032
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Jul 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.
Conditions
- Solid Tumor
- Locally Advanced Non-Small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
Interventions
DS-3939aDrug
DS-3939a will be administered as an IV infusion.
PembrolizumabDrug
Pembrolizumab will be administered as an IV infusion.
CarboplatinDrug
Carboplatin will be administered as an IV infusion.
PemetrexedDrug
Pemetrexed will be administered as an IV infusion.
DS-1103aDrug
DS-1103a will be administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: During first cycle (Cycle length=21 days)
- Part 1: Number of Participants With TEAEsTime frame: Up to approximately 4 years
- Part 2: Objective Response (OR) Per RECIST v1.1 as Assessed by InvestigatorTime frame: Up to approximately 4 years
Locations
76 sites in 13 countries. Site status is shown where the registry gives one.
Highlands Oncology Group (Hog) - Fayetteville
Fayetteville, Arkansas · Recruiting
UCLA Health
Los Angeles, California · Not yet recruiting
Moffitt Cancer Center - Magnolia Campus
Tampa, Florida · Not yet recruiting
Oregon Health & Science University
Portland, Oregon · Not yet recruiting
Lifespan Cancer Institute - Rhode Island Hospital
Providence, Rhode Island · Not yet recruiting
The University of Texas Md Anderson Cancer Center
Houston, Texas · Not yet recruiting
Inova Schar Cancer Institute
Fairfax, Virginia · Recruiting
Instituto Alexander Fleming
Buenos Aires, Argentina · Not yet recruiting
Instituto Oncologico de Cordoba (Ionc) - Fundacion Richardet Longo
Córdoba, Argentina · Not yet recruiting
Sanatorio Parque
Rosario, Argentina · Not yet recruiting
Cer San Juan - Centro Polivalente de Asistencia E Investigacion Clinica
San Juan, Argentina · Not yet recruiting
Clinica Viedma S.A.
Viedma, Argentina · Not yet recruiting
Medizinische Universitat Innsbruck
Innsbruck, Austria · Not yet recruiting
Karl Landsteiner Institut Fur Lungenforschung Und Pneumologische Onkologie
Vienna, Austria · Not yet recruiting
Universite Libre de Bruxelles (Ulb) - Institut Jules
Brussels, Belgium · Not yet recruiting
Jessa Ziekenhuis - Hartcentrum Hasselt
Sint-Truiden, Belgium · Not yet recruiting
Fundacao Pio Xii-Hospital de Cancer de Barretos
Barretos, Brazil · Not yet recruiting
Liga Norte Riograndense Contra O Cancer - Pesquisa Clinica
Natal, Brazil · Not yet recruiting
Irmandade Da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Brazil · Not yet recruiting
Hospital Sao Lucas Da Pucrs
Porto Alegre, Brazil · Not yet recruiting
Obras Sociais Irma Dulce - Centro de Pesquisa Oncologica E Clinica (Cpoc)
Salvador, Brazil · Not yet recruiting
Hospital Israelita Albert Einstein
São Paulo, Brazil · Not yet recruiting
Beijing Chest Hospital, Capital Medical University
Beijing, China · Not yet recruiting
Jilin Cancer Hospital
Changchun, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, China · Not yet recruiting
The First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine (Zhejiang Provincial First Hos
Hangzhou, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Not yet recruiting
Tianjin Medical University Cancer Institute and Hospital
Hexi District, Tianjin, China · Not yet recruiting
Jiamusi Cancer Hospital
Jiamusi, China · Not yet recruiting
Shandong University - Shandong Cancer Hospital
Jinan, China · Not yet recruiting
Lin Yi Cancer Hospital
Linyi, China · Not yet recruiting
Shanghai East Hospital
Shanghai, China · Not yet recruiting
Taizhou Hospital of Zhejiang Province
Taizhou, China · Not yet recruiting
Hubei Cancer Hospital
Wuhan, China · Not yet recruiting
Henan Provincial Cancer Hospital
Zhengzhou, China · Not yet recruiting
Aphm - Hopital Nord
Marseille, France · Not yet recruiting
Centre Hospitalier Universitaire de Montpellier (Chu Montpellier) - Hopital Lapeyronie
Montpellier, France · Not yet recruiting
Hospitalier Paris Saint-Joseph
Paris, France · Not yet recruiting
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.